News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,875 Results
Type
Article (41077)
Company Profile (267)
Press Release (680521)
Multimedia
Podcasts (89)
Webinars (17)
Section
Business (204729)
Career Advice (2024)
Deals (35545)
Drug Delivery (113)
Drug Development (81518)
Employer Resources (173)
FDA (16424)
Job Trends (14952)
News (346554)
Policy (32790)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2573)
Accelerated approval (31)
Adcomms (25)
Allergies (142)
Alliances (49584)
ALS (169)
Alzheimer's disease (1668)
Antibody-drug conjugate (ADC) (308)
Approvals (16690)
Artificial intelligence (517)
Autoimmune disease (153)
Automation (39)
Bankruptcy (361)
Best Places to Work (11642)
BIOSECURE Act (20)
Biosimilars (188)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (57)
Breast cancer (637)
Cancer (4801)
Cardiovascular disease (398)
Career advice (1709)
Career pathing (36)
CAR-T (280)
CDC (47)
Celiac Disease (2)
Cell therapy (739)
Cervical cancer (36)
Clinical research (69596)
Collaboration (1703)
Company closure (4)
Compensation (1156)
Complete response letters (55)
COVID-19 (2796)
CRISPR (88)
C-suite (842)
Cystic fibrosis (143)
Data (6213)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (500)
Diagnostics (6688)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (251)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (233)
Earnings (90171)
Editorial (58)
Employer branding (21)
Employer resources (152)
Events (117279)
Executive appointments (971)
FDA (19536)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1466)
Gene editing (194)
Generative AI (44)
Gene therapy (594)
GLP-1 (967)
Government (4702)
Grass and pollen (6)
Guidances (383)
Healthcare (18885)
HIV (58)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (249)
Immuno-oncology (57)
Indications (110)
Infectious disease (3068)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (119)
Intellectual property (248)
Interviews (315)
IPO (16648)
IRA (51)
Job creations (3643)
Job search strategy (1429)
JPM (59)
Kidney cancer (16)
Labor market (85)
Layoffs (548)
Leadership (31)
Legal (7960)
Liver cancer (91)
Longevity (14)
Lung cancer (648)
Lymphoma (375)
Machine learning (42)
Management (59)
Manufacturing (793)
MASH (164)
Medical device (13768)
Medtech (13821)
Mergers & acquisitions (19967)
Metabolic disorders (1272)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (315)
Neuropsychiatric disorders (88)
Neuroscience (2892)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4514)
Now hiring (68)
Obesity (598)
Opinion (258)
Ovarian cancer (166)
Pain (197)
Pancreatic cancer (226)
Parkinson's disease (280)
Partnered (33)
Patents (495)
Patient recruitment (488)
Peanut (56)
People (58885)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21697)
Phase 2 (30634)
Phase 3 (22828)
Pipeline (5261)
Policy (286)
Postmarket research (2565)
Preclinical (9199)
Press Release (64)
Prostate cancer (237)
Psychedelics (51)
Radiopharmaceuticals (279)
Rare diseases (833)
Real estate (5955)
Recruiting (70)
Regulatory (24498)
Reports (52)
Research institute (2392)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (81)
Schizophrenia (147)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3619)
State (2)
Stomach cancer (17)
Supply chain (105)
Tariffs (84)
The Weekly (62)
Vaccines (1057)
Venture capital (88)
Weight loss (382)
Women's health (91)
Worklife (18)
Date
Today (212)
Last 7 days (630)
Last 30 days (2140)
Last 365 days (30008)
2026 (3379)
2025 (30196)
2024 (35246)
2023 (40090)
2022 (51204)
2021 (55764)
2020 (54123)
2019 (46543)
2018 (35022)
2017 (32119)
2016 (31486)
2015 (37553)
2014 (31318)
2013 (26349)
2012 (28570)
2011 (29263)
2010 (27329)
Location
Africa (739)
Alabama (83)
Alaska (7)
Arizona (309)
Arkansas (13)
Asia (39227)
Australia (6411)
California (11278)
Canada (3280)
China (1095)
Colorado (477)
Connecticut (475)
Delaware (335)
Europe (84537)
Florida (1686)
Georgia (355)
Hawaii (3)
Idaho (61)
Illinois (859)
India (65)
Indiana (519)
Iowa (22)
Japan (428)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1380)
Massachusetts (8079)
Michigan (324)
Minnesota (628)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2996)
New Mexico (28)
New York (2970)
North Carolina (1448)
North Dakota (8)
Northern California (5510)
Ohio (332)
Oklahoma (21)
Oregon (41)
Pennsylvania (2275)
Puerto Rico (24)
Rhode Island (47)
South America (1109)
South Carolina (66)
South Dakota (1)
Southern California (4388)
Tennessee (174)
Texas (1737)
United States (39957)
Utah (334)
Vermont (1)
Virginia (260)
Washington D.C. (81)
Washington State (918)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
721,875 Results for "moderna inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans
Moderna’s mRNA-1010 was expected to contribute $1 billion to the company’s coffers by 2028. That plan is now out the window after the FDA refused to even look at the application.
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
Editorial
All the Ways Moderna’s Flu Vaccine Rejection Letter Shocked Us
The FDA issued a rare Refusal-to-File letter to Moderna over its mRNA-based influenza vaccine application, in an unusual move that sent the biotech’s shares tumbling.
February 11, 2026
·
4 min read
·
Dan Samorodnitsky
Vaccines
FDA Refuses To Review Moderna’s mRNA Flu Vaccine, Claims Trial Inadequacies
After receiving a letter directly from CBER Director Vinay Prasad, Moderna said the FDA had previously signed off on the use of a licensed flu vaccine as a comparator for a Phase 3 study of mRNA-1010.
February 11, 2026
·
4 min read
·
Tristan Manalac
FDA
FDA’s Prasad Weathers Personal Controversy, Internal Strife Amid Moderna Imbroglio
Vinay Prasad, the FDA’s Center for Biologics Evaluation and Research head, is accused of interpersonal impropriety as pushback builds against his decision to reject Moderna’s influenza vaccine candidate.
February 12, 2026
·
2 min read
·
Dan Samorodnitsky
Regulatory
HHS Backs Prasad Amid Moderna Flu Shot Blowback
An unnamed FDA official also told reporters that it would be good for Moderna to “show some humility” and admit that it didn’t follow the regulator’s recommendations in testing its mRNA flu vaccine.
February 12, 2026
·
2 min read
·
Tristan Manalac
Business
Moderna Hits 2025 Revenue Goal as Operating Costs Fall Faster than Forecast
While Moderna’s full-year sales landed in the upper end of its target range, Jefferies analysts said further reductions are needed if the biotech hopes to hit its 2028 break-even target.
January 12, 2026
·
2 min read
·
Nick Paul Taylor
Deals
Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M
Moderna will continue to lead clinical development and manufacturing of the asset, while Recordati will handle commercialization of mRNA-3927, which is under development for the rare metabolic disorder propionic acidemia.
January 30, 2026
·
1 min read
·
Annalee Armstrong
Vaccines
Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg
Growing opposition to vaccines in the U.S., driven by recent government policy changes, makes it difficult to see a return on investment in vaccine development, Moderna CEO Stéphane Bancel said this week.
January 23, 2026
·
2 min read
·
Tristan Manalac
Cancer
Moderna Claims Early Victory for Cancer Antigen in Melanoma
Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with efficacy increasing to 67% in those positive for PD-L1.
October 13, 2025
·
2 min read
·
Tristan Manalac
influenza
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine
The money replaces a small portion of a contract Moderna lost when the Department of Health and Human Services canceled $760 million in backing to develop the vaccine, called mRNA-1018.
December 18, 2025
·
1 min read
·
Dan Samorodnitsky
1 of 72,188
Next
